Reports Q1 revenue $5.8B, consensus $5.62B. Rainer Blair, president and CEO, stated, “We had a good start to 2024, with our team delivering better-than-expected revenue, earnings and cash flow. We were especially pleased to see improving order trends in our bioprocessing business and believe we continued to gain market share in our molecular diagnostics business at Cepheid.”